Predicted impact of intravenous thrombolysis on prognosis of general population of stroke patients: Simulation model

British Medical Journal

Volumn 319, Issue 7205, 1999, Pages 288-289

  Jørgensen, Henrik Stig ^a   Nakayama, Hirofumi ^a   Kammersgaard, Lars Peter ^a   Raaschou, Hans Otto ^a   Olsen, Tom Skyhøj ^b  

^a BISPEBJERG HOSPITAL   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT;

ARTICLE; BLEEDING; CLINICAL TRIAL; FIBRINOLYTIC THERAPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; STROKE;

EID: 0033620868     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.319.7205.288     Document Type: Article

References (4)

1. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for accute ischemic stroke. N Engl J Med 1995;333:1581-7.
2. The ECASS Study Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA 1995;274:1017-25.
3. The ECASS II Study Group. Randommised double-blind placebo- controlled trial of thrombolytic therapy with intravenous alteplace in acute ischaemic stroke (ECASS II). Lancet 1998;352:1245-51.
4. Jørgensen HS, Nakayama H, Raaschou HO, Olsen TS. Effect of blood pressure and diabetes on stroke in progression. Lancet 1994;344:156-9.